StreetInsider.com News Articles

Form 4 Nuo Therapeutics, Inc. For: Jun 05 Filed by: JORDEN DAVID EMERSON

Fri, 05 Jun 2026 18:34:00 -0400

si-local-file:///var/storage/secattach/20260605/26612520.html

Form 4 Nuo Therapeutics, Inc. For: Jun 05 Filed by: JORDEN DAVID EMERSON

Fri, 05 Jun 2026 18:34:00 -0400

si-local-file:///var/storage/secattach/20260605/26612520.html

Form SCHEDULE 13D/A Nuo Therapeutics, Inc. Filed by: Pittman Scott M.

Wed, 03 Jun 2026 11:04:00 -0400

si-local-file:///var/storage/secattach/20260603/26597220.html

Form SCHEDULE 13D/A Nuo Therapeutics, Inc. Filed by: Pittman Scott M.

Wed, 03 Jun 2026 11:04:00 -0400

si-local-file:///var/storage/secattach/20260603/26597220.html

Form 8-K Nuo Therapeutics, Inc. For: May 29

Wed, 03 Jun 2026 06:00:00 -0400

si-local-file:///var/storage/secattach/20260603/26594659.html

Form 8-K Nuo Therapeutics, Inc. For: May 29

Wed, 03 Jun 2026 06:00:00 -0400

si-local-file:///var/storage/secattach/20260603/26594659.html

Form 4 Nuo Therapeutics, Inc. For: May 29 Filed by: Pittman Scott M.

Tue, 02 Jun 2026 21:55:00 -0400

si-local-file:///var/storage/secattach/20260602/26594114.html

Form 4 Nuo Therapeutics, Inc. For: May 29 Filed by: Pittman Scott M.

Tue, 02 Jun 2026 21:55:00 -0400

si-local-file:///var/storage/secattach/20260602/26594114.html

Form 4/A Nuo Therapeutics, Inc. For: Jan 23 Filed by: Pittman Scott M.

Tue, 02 Jun 2026 21:50:00 -0400

si-local-file:///var/storage/secattach/20260602/26594105.html

Form 4/A Nuo Therapeutics, Inc. For: Jan 23 Filed by: Pittman Scott M.

Tue, 02 Jun 2026 21:50:00 -0400

si-local-file:///var/storage/secattach/20260602/26594105.html

Nuo Therapeutics, Inc. (AURX) Reports In-Line Q1 EPS

Thu, 14 May 2026 17:53:03 -0400

Nuo Therapeutics, Inc. (OTC: AURX) reported Q1 EPS of ($0.01), in-line with the analyst estimate of ($0.01). Revenue for the quarter came in at $1.3 million versus the consensus estimate of $1.02 million.

For earnings history and earnings-related data on Nuo Therapeutics, Inc. (AURX) click here.

Nuo Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

Thu, 14 May 2026 17:15:00 -0400

HOUSTON, May 14, 2026 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial-stage medical device company focused on developing and marketing regenerative therapies for chronic wound care, announced financial results for the first quarter ended March 31, 2026 and provided an operational and business update.

First Quarter 2026 Financial Summary

Total revenues of approximately $1.3 million (including approximately $1,224,000 of product revenues) increased 169% over the 2025 first quarter and 20% over last year’s fourth quarter
Aurix branded product revenues were up over 30% sequentially versus 2025 fourth quarter
Net operating

Nuo Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

Thu, 14 May 2026 17:15:00 -0400

First Quarter 2026 Financial Summary

Total revenues of approximately $1.3 million (including approximately $1,224,000 of product revenues) increased 169% over the 2025 first quarter and 20% over last year’s fourth quarter
Aurix branded product revenues were up over 30% sequentially versus 2025 fourth quarter
Net operating

Nuo Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

Thu, 14 May 2026 17:15:00 -0400

First Quarter 2026 Financial Summary

Total revenues of approximately $1.3 million (including approximately $1,224,000 of product revenues) increased 169% over the 2025 first quarter and 20% over last year’s fourth quarter
Aurix branded product revenues were up over 30% sequentially versus 2025 fourth quarter
Net operating

Nuo Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

Thu, 14 May 2026 17:15:00 -0400

First Quarter 2026 Financial Summary

Total revenues of approximately $1.3 million (including approximately $1,224,000 of product revenues) increased 169% over the 2025 first quarter and 20% over last year’s fourth quarter
Aurix branded product revenues were up over 30% sequentially versus 2025 fourth quarter
Net operating

Form 8-K Nuo Therapeutics, Inc. For: May 14

Thu, 14 May 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260514/26496571.html

Form 8-K Nuo Therapeutics, Inc. For: May 14

Thu, 14 May 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260514/26496571.html

Form 10-Q Nuo Therapeutics, Inc. For: Mar 31

Thu, 14 May 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260514/26496398.html

Form 10-Q Nuo Therapeutics, Inc. For: Mar 31

Thu, 14 May 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260514/26496398.html

Form 10-K Nuo Therapeutics, Inc. For: Dec 31

Mon, 30 Mar 2026 17:42:00 -0400

si-local-file:///var/storage/secattach/20260330/26241540.html

Form 10-K Nuo Therapeutics, Inc. For: Dec 31

Mon, 30 Mar 2026 17:42:00 -0400

si-local-file:///var/storage/secattach/20260330/26241540.html

Form SCHEDULE 13G/A Nuo Therapeutics, Inc. Filed by: Jacobs Paul Anthony

Thu, 12 Feb 2026 16:44:00 -0400

si-local-file:///var/storage/secattach/20260212/25992871.html

Form SCHEDULE 13G/A Nuo Therapeutics, Inc. Filed by: Jacobs Paul Anthony

Thu, 12 Feb 2026 16:44:00 -0400

si-local-file:///var/storage/secattach/20260212/25992871.html

Form 4 Nuo Therapeutics, Inc. For: Jan 23 Filed by: Pittman Scott M.

Mon, 26 Jan 2026 18:44:00 -0400

si-local-file:///var/storage/secattach/20260126/25894503.html

Form 4 Nuo Therapeutics, Inc. For: Jan 23 Filed by: Pittman Scott M.

Mon, 26 Jan 2026 18:44:00 -0400

si-local-file:///var/storage/secattach/20260126/25894503.html